Continuus Pharmaceuticals To Build In-House Small Molecule Manufacturing Facility In Massachusetts
DoD/HHS contract will enable onshore production of three vital medicines to treat critically ill patients, including those with COVID-19
Company will build the first GMP-certified end-to-end manufacturing facility using its proprietary technology for the production of small-molecule medicines
Woburn, MA /PRNewswire/ - CONTINUUS Pharmaceuticals Inc., an innovator in transforming production of small-molecule pharmaceuticals with its proprietary Integrated Continuous Manufacturing (ICM) technology, today announced receipt of a $69.3 million U.S. government contract to facilitate domestic production of three vital medicines used to treat critically ill patients, including those with COVID-19. The contract, awarded by the Department of Defense (DoD) in conjunction with the Department of Health and Human Services (HHS), will also enable construction of the country s first Good Manufacturin
Share this article
Share this article
WOBURN, Mass., Jan. 21, 2021 /PRNewswire/ CONTINUUS Pharmaceuticals Inc., an innovator in transforming production of small-molecule pharmaceuticals with its proprietary Integrated Continuous Manufacturing (ICM) technology, today announced receipt of a $69.3 million U.S. government contract to facilitate domestic production of three vital medicines used to treat critically ill patients, including those with COVID-19. The contract, awarded by the Department of Defense (DoD) in conjunction with the Department of Health and Human Services (HHS), will also enable construction of the country s first Good Manufacturing Practices (GMP)-certified facility for end-to-end, ICM-driven production of small-molecule drugs, including marketed products, generic medications, and investigational therapies through all phases of clinical trials and a product s lifecycle.
Continuus lands $69.3m US drug manufacturing contract The small-molecule pharmaceuticals manufacturer secured a DoD/HHS government contract to manufacture critical medicines for a range of conditions.
Continuus Pharmaceuticals, a firm that uses proprietary integrated continuous manufacturing (ICM) technology to manufacture drugs, has been granted a $69.3m (57 EUR) contract to manufacture three different medicines. The contract, awarded by the US Department of Defense (DoD) and Department of Health and Human Services (HHS), also will be used for construction of the country’s first GMP-certified facility for ICM-driven facility of small-molecule marketed drugs, generic medicines and investigational therapies, through all clinical trial phases and the rest of a product’s lifecycle.